by John and his colleagues, the charity set out on its journey with limited resources, considerable energy and some useful business connections although the reputations of the young Walton and the more experienced Nattrass gave the charity great credibility within the research and healthcare community. When Richard Attenborough was moved to join them and give his full support to the charity in 1962, after meeting a group of boys with Duchenne muscular dystrophy, he brought an additional dimension with his celebrity connections from the glittering world of film and entertainment in which he was to become a huge figure in this country and indeed internationally.
John was the Chairman of the charity for 25 years, following Nattrass, after serving as Chairman of both the Research Committee and the Medical and Social Services Committee. As his career developed, his commitments and responsibilities grew to take more and more of his time and John had to take a less timeconsuming role with the charity. It is entirely fitting that his immeasurable contribution was recognised with his appointment as the charity's Honorary Life President.
In 1989, John's contribution to public life in fields such as medicine, science and education was recognised with his elevation to the House of Lords and he rapidly gained a well-earned reputation as an extremely effective and influential Parliamentarian. As a crossbencher (non-Party member), John commands the utmost respect and makes expert contributions to House of Lords debates on topics such as embryology, mitochondrial research and improving healthcare.
It is clear the John Walton Muscular Dystrophy Research Centre will continue to be at the forefront of expert clinical care and research not just in the UK but 
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on the international stage too. John is a forward thinker who understood from the very start of his career the need to establish collaborative approaches and partnerships and the Centre very much reflects his approach. We are seeing huge strides in research and care led by Newcastle today, building on the vision and contribution of John and his colleagues over many years. Indeed, we have seen a first treatment licensed by the EMA to target nonsense mutations as the underlying cause of Duchenne muscular dystrophy affecting some 11-13% of boys with the condition. Given the number of potential treatments for muscle-wasting conditions now in clinical trials we can anticipate more treatments coming through to patients as a direct result of the contribution of John Walton to our field.
John is much loved and respected as the founder of the charity, a man whose long term vision, high standards and integrity laid the foundations for our work. We are deeply grateful for John's huge contribution both to the individuals and families affected by muscular dystrophy and related neuromuscular conditions and, of course, to our charity. It is right to say his contribution is unrivalled and it is difficult to imagine it can ever be equalled let alone surpassed.
